Status:
ENROLLING_BY_INVITATION
Long Term Follow Up KET-PD
Lead Sponsor:
Yale University
Collaborating Sponsors:
Fox (Michael J.) Foundation for Parkinson's Research
Yale School of Medicine Center for Brain Mind Health
Conditions:
Parkinson's Disease
Depression
Eligibility:
All Genders
40-80 years
Brief Summary
The purpose of this study is to examine a) the longer-term effects of ketamine for treating depression in Parkinson's disease (PD) and b) the effects of CBT on maintaining the effects of ketamine.
Detailed Description
This is a roll-out study from the ongoing clinical trial (KET-PD trial; NCT04944017, HIC 2000030394). We will adopt an implementation science approach to have participants across ketamine and placebo ...
Eligibility Criteria
Inclusion
- Eligibility is determined in the ongoing parent clinical trial (KET-PD trial; NCT04944017, HIC 2000030394).
Exclusion
Key Trial Info
Start Date :
October 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 21 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT06164756
Start Date
October 18 2023
End Date
December 21 2025
Last Update
July 11 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yale New Haven Hospital
New Haven, Connecticut, United States, 06510